| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5698 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2942 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1764 | 2020 |
| Synthesis, characterization, applications, and challenges of iron oxide nanoparticles A Ali, H Zafar, M Zia, I ul Haq, AR Phull, JS Ali, A Hussain Nanotechnology, science and applications, 49-67, 2016 | 1732 | 2016 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1421 | 2021 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 902* | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 429* | 2022 |
| Remittances, growth and poverty: New evidence from Asian countries KS Imai, R Gaiha, A Ali, N Kaicker Journal of Policy Modeling 36 (3), 524-538, 2014 | 376 | 2014 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10274), 605, 2021 | 350 | 2021 |
| Effect of ZnO Nanoparticles on Brassica nigra Seedlings and Stem Explants: Growth Dynamics and Antioxidative Response H Zafar, A Ali, JS Ali, IU Haq, M Zia Frontiers in plant science 7, 535, 2016 | 305 | 2016 |
| Antioxidant, cytotoxic and antimicrobial activities of green synthesized silver nanoparticles from crude extract of Bergenia ciliata AR Phull, Q Abbas, A Ali, H Raza, M Zia, I Haq Future Journal of Pharmaceutical Sciences 2 (1), 31-36, 2016 | 291 | 2016 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 288 | 2022 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 285 | 2021 |
| Prevalence of Adhesion and Regulation of Biofilm‐Related Genes in Different Clones of Staphylococcus aureus SS Atshan, M Nor Shamsudin, Z Sekawi, LTT Lung, RA Hamat, ... BioMed Research International 2012 (1), 976972, 2012 | 215 | 2012 |
| Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19 M Imran, M Kumar Arora, SMB Asdaq, SA Khan, SI Alaqel, ... Molecules 26 (19), 5795, 2021 | 206 | 2021 |
| Elemental zinc to zinc nanoparticles: Is ZnO NPs crucial for life? Synthesis, toxicological, and environmental concerns A Ali, AR Phull, M Zia Nanotechnology Reviews 7 (5), 413-441, 2018 | 204 | 2018 |
| Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021 SE Vollset, HS Ababneh, YH Abate, C Abbafati, R Abbasgholizadeh, ... The Lancet 403 (10440), 2204-2256, 2024 | 202 | 2024 |
| The impact of macroeconomic instability on social progress: an empirical analysis of Pakistan A ALI National College of Business Administration & Economics Lahore, 2015 | 187 | 2015 |
| Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy G Levent, A Ali, A Ahmet, EC Polat, Ç Aytaç, E Ayşe, S Ahmet Journal of Translational Medicine 4, 1-6, 2006 | 178 | 2006 |
| Breast-cancer screening with trained volunteers in a rural area of Sudan: a pilot study DO Abuidris, A Elsheikh, M Ali, H Musa, E Elgaili, AO Ahmed, I Sulieman, ... The lancet oncology 14 (4), 363-370, 2013 | 155 | 2013 |
Rukman Awang HamatUniversiti Putra MalaysiaПідтверджена електронна адреса в upm.edu.my
